Ipx-461 -

Title Page

• Improved therapeutic window: By focusing on a precise biological driver, IPX-461 aims to widen the gap between effective doses and toxic doses, which may allow clearer benefits for patients.
• Addressing unmet needs: Candidates like IPX-461 often target conditions where current options are limited, resistant, or produce substantial side effects—giving clinicians and patients new choices.

The safety profile of IPX-461, like other TZDs, includes potential adverse effects such as:

2. What’s in the Box?

What it aims to do

He found himself hurtling through a tunnel of code, surrounded by swirling patterns of 1s and 0s. The journey was disorienting, yet exhilarating, as if he were surfing through the very heart of the internet. IPX-461 was taking him on a wild ride, and Alex was powerless to resist its pull. IPX-461

IPX-461 works by specifically targeting the HAO1 gene, which is involved in the production of the glycolate oxidase 1 enzyme. By reducing HAO1 expression, IPX-461 decreases the conversion of glycolate to glyoxylate, a precursor to oxalate. This results in lower oxalate levels, which can slow disease progression in PH1 and FSGS. Title Page